Table 2.
Treatments of patients with thymic hyperplasia
| Patient # | First line treatment | First line treatment | Second line treatment | Cycles |
|---|---|---|---|---|
|
| ||||
| Cycles | ||||
| 1 | Cisplatine+Docetaxel | 2 | ||
| 2 | Carboplatine+Docetaxel | 4 | ||
| 3 | Cisplatine+ Vinorelbine | 6 | ||
| 4 | Cisplatine+ Vinorelbine | 6 | ||
| 5 | Cisplatine+Docetaxel | 6 | ||
| 6 | Cisplatine+Vinorelbine | 4 | ||
| 7 | Carboplatine+Gemcitabine | 4 | ||
| 8 | Carboplatine+Gemcitabine | 4 | ||
| 9 | Cisplatine+Navelbine | 2 | ||
| 10 | Cisplatine+ Vinorelbine | Pemetrexed | 2 | |
| 11 | Cisplatine+Gemcitabine | 2 | ||
| 12 | Cisplatine+Docetaxel | 2 | ||
| 13 | Cisplatine+ Vinorelbine | Pemetrexed | 2 |